Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study

Bruin Pollard; Elizabeth C. Utterson; Charles M. Samson; Carrie C. Coughlin

doi:10.1111/pde.14985

Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study

Bruin Pollard, Elizabeth C. Utterson, Charles M. Samson, Carrie C. Coughlin

Research output: Contribution to journal › Article › peer-review

Abstract

Paradoxically, immunosuppressive therapy for inflammatory bowel disease (IBD) can induce psoriasiform or eczematous eruptions. This case-control study identified infliximab exposure, Crohn's disease, and history of inflammatory skin conditions as significant risk factors for these eruptions in children with IBD. Our results also showed possible trends in age and race.

Original language	English
Pages (from-to)	563-566
Number of pages	4
Journal	Pediatric Dermatology
Volume	39
Issue number	4
DOIs	https://doi.org/10.1111/pde.14985
State	Published - Jul 1 2022

Keywords

Crohn's disease
adalimumab
eczema
immunosuppression
inflammatory bowel disease
infliximab
psoriasis

Access to Document

10.1111/pde.14985

Cite this

@article{d824be23e1b8459292b27609a0c0d75c,

title = "Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study",

abstract = "Paradoxically, immunosuppressive therapy for inflammatory bowel disease (IBD) can induce psoriasiform or eczematous eruptions. This case-control study identified infliximab exposure, Crohn's disease, and history of inflammatory skin conditions as significant risk factors for these eruptions in children with IBD. Our results also showed possible trends in age and race.",

keywords = "Crohn's disease, adalimumab, eczema, immunosuppression, inflammatory bowel disease, infliximab, psoriasis",

author = "Bruin Pollard and Utterson, {Elizabeth C.} and Samson, {Charles M.} and Coughlin, {Carrie C.}",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = jul,

day = "1",

doi = "10.1111/pde.14985",

language = "English",

volume = "39",

pages = "563--566",

journal = "Pediatric Dermatology",

issn = "0736-8046",

number = "4",

}

TY - JOUR

T1 - Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease

T2 - A case-control study

AU - Pollard, Bruin

AU - Utterson, Elizabeth C.

AU - Samson, Charles M.

AU - Coughlin, Carrie C.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Paradoxically, immunosuppressive therapy for inflammatory bowel disease (IBD) can induce psoriasiform or eczematous eruptions. This case-control study identified infliximab exposure, Crohn's disease, and history of inflammatory skin conditions as significant risk factors for these eruptions in children with IBD. Our results also showed possible trends in age and race.

AB - Paradoxically, immunosuppressive therapy for inflammatory bowel disease (IBD) can induce psoriasiform or eczematous eruptions. This case-control study identified infliximab exposure, Crohn's disease, and history of inflammatory skin conditions as significant risk factors for these eruptions in children with IBD. Our results also showed possible trends in age and race.

KW - Crohn's disease

KW - adalimumab

KW - eczema

KW - immunosuppression

KW - inflammatory bowel disease

KW - infliximab

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85127306479&partnerID=8YFLogxK

U2 - 10.1111/pde.14985

DO - 10.1111/pde.14985

M3 - Article

C2 - 35342990

AN - SCOPUS:85127306479

SN - 0736-8046

VL - 39

SP - 563

EP - 566

JO - Pediatric Dermatology

JF - Pediatric Dermatology

IS - 4

ER -

Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this